Search
Polyethylene glycol 400
go.drugbank.com/drugs/DB11077ApprovedInvestigationalIt is used in ophthalmic solutions for the relief of burning, irritation and/or discomfort that follows dryness of the eye [L1785]. … It is very hydrophilic, which renders it a useful ingredient in drug formulations to augment the solubility and bioavailability of weakly water-soluble drugs.
Mixtures: i-Drops LUBRICANT EYE DROPS, i-Drops LUBRICANT EYE DROPSCategories: Compounds used in a research, industrial, or household settingZoliflodacin
go.drugbank.com/drugs/DB12817ApprovedInvestigational[A275268] Zoliflodacin is a first-in-class spiropyrimidinetrione antibiotic designed to address this need by inhibiting bacterial type II topoisomerases (DNA gyrase and topoisomerase IV), thereby blocking … FDA in December 2025, following Fast Track, Qualified Infectious Disease Product, and Priority Review designations.[L54743,L54803]
Categories: Topoisomerase II InhibitorsLevodopa
go.drugbank.com/drugs/DB01235ApprovedInvestigationalLevodopa is a prodrug of dopamine that is administered to patients with Parkinson's due to its ability to cross the blood-brain barrier[Label]. … Levodopa can be metabolised to dopamine on either side of the blood-brain barrier and so it is generally administered with a dopa decarboxylase inhibitor like carbidopa to prevent metabolism until after
Mixtures: LEV/CAR/EN AL100/25/200, LEV/CAR/EN AL200/50/200Pirfenidone
go.drugbank.com/drugs/DB04951ApprovedInvestigational[A251370] It is an antifibrotic agent with anti-inflammatory and antioxidant properties [A251370] that is used to treat idiopathic pulmonary fibrosis (IPF),[L26801] which is a chronic, progressive form … Pirfenidone is a synthetic pyridone drug.
Abrocitinib
go.drugbank.com/drugs/DB14973ApprovedInvestigational[L39784] On January 14, 2022, the FDA approved abrocitinib for the treatment of refractory, moderate-to-severe AD in adults whose disease is not adequately controlled with other systemic drug products, … [L39779] Health Canada also approved the use of abrocitinib in pediatric patients 12 years and older.[L42395]
Aprocitentan
go.drugbank.com/drugs/DB15059ApprovedInvestigational[A263386,L50261] Aprocitentan was approved by the FDA in March 2024 for the treatment of hypertension in patients inadequately controlled with standard therapy. … [L50261] It was the first antihypertensive employing a novel mechanism to be approved in almost 40 years.[L50261]
Grazoprevir
go.drugbank.com/drugs/DB11575ApprovedIn a joint recommendation published in 2016, the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) recommend Grazoprevir as first line therapy … It can be used in patients with compensated cirrhosis, human immunodeficiency virus co-infection, or severe kidney disease.
ATG-Fresenius S
go.drugbank.com/drugs/DB05320InvestigationalATG-Fresenius S is a concentrated anti-human T-lymphocyte immunoglobulin preparation derived from rabbits after immunization with a T-lympoblast cell line. … ATG-Fresenius S is an immunosuppressive product for the prevention and treatment of acute rejection following organ transplantation.
Asciminib
go.drugbank.com/drugs/DB12597ApprovedInvestigational[A241065] Asciminib is unique in that it acts as an allosteric inhibitor, binding at the myristoyl pocket of the BCR-ABL1 protein and locking it into an inactive conformation. … More specifically, it is an inhibitor of the ABL1 kinase activity of the BCR-ABL1 fusion protein[L38995] which serves as a driver of CML proliferation in most patients with the disease.